C4 Therapeutics, Inc. (CCCC)

NASDAQ: CCCC · IEX Real-Time Price · USD
5.68
-0.29 (-4.86%)
At close: May 17, 2024, 4:00 PM
5.69
+0.01 (0.18%)
After-hours: May 17, 2024, 7:54 PM EDT
-4.86%
Market Cap 389.44M
Revenue (ttm) 20.04M
Net Income (ttm) -126.07M
Shares Out 68.81M
EPS (ttm) -2.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 813,934
Open 5.99
Previous Close 5.97
Day's Range 5.62 - 6.01
52-Week Range 1.06 - 11.88
Beta 3.19
Analysts Buy
Price Target 8.88 (+56.34%)
Earnings Date May 8, 2024

About CCCC

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CF... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 2, 2020
Employees 145
Stock Exchange NASDAQ
Ticker Symbol CCCC
Full Company Profile

Financial Performance

In 2023, CCCC's revenue was $20.76 million, a decrease of -33.25% compared to the previous year's $31.10 million. Losses were -$132.49 million, 3.37% more than in 2022.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CCCC stock is "Buy." The 12-month stock price forecast is $8.88, which is an increase of 56.34% from the latest price.

Price Target
$8.88
(56.34% upside)
Analyst Consensus: Buy
Stock Forecasts

News

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Cri...

10 days ago - GlobeNewsWire

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

19 days ago - GlobeNewsWire

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

5 weeks ago - GlobeNewsWire

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

5 weeks ago - GlobeNewsWire

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis CFT1946 Data ...

2 months ago - GlobeNewsWire

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Collaboration Focused on Two Targeted Protein Degraders from C4T's Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research...

2 months ago - GlobeNewsWire

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024 Phase 1 Dose Escalation Trials for CFT7455 and CFT1946 Continue to Progress; Data from Both Trials Expected ...

3 months ago - GlobeNewsWire

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials

4 months ago - GlobeNewsWire

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science t...

4 months ago - GlobeNewsWire

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science t...

4 months ago - GlobeNewsWire

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Data Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity

5 months ago - GlobeNewsWire

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for Three Additional Targets Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for T...

5 months ago - GlobeNewsWire

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

WATERTOWN, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science t...

6 months ago - GlobeNewsWire

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors Owen Hughes, Accomplished ...

6 months ago - GlobeNewsWire

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Portfolio Decision to Prioritize Ongoing Phase 1/2 Trials of CFT7455, an IKZF1/3 Degrader, and CFT1946, a BRAF V600 Degrader

7 months ago - GlobeNewsWire

C4 Therapeutics Announces Chief Financial Officer Succession

WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science ...

9 months ago - GlobeNewsWire

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared

10 months ago - GlobeNewsWire

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science t...

11 months ago - GlobeNewsWire

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) sci...

11 months ago - GlobeNewsWire

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

WATERTOWN, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science t...

11 months ago - GlobeNewsWire

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

C4 Therapeutics to Receive a $10 Million Upfront Payment, a $25 Million Equity Investment and is Eligible to Receive up to $357 Million for Development and Commercial Milestones Plus Royalties on Net ...

1 year ago - GlobeNewsWire

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC ™ Degrader; Phase 1/2 Clinical Trial Enrolling Patients

1 year ago - GlobeNewsWire

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science ...

1 year ago - GlobeNewsWire

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023

1 year ago - GlobeNewsWire